Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Rhinovirus Clear all
Completed No phase listed Observational Accepts healthy volunteers

Ozone and Rhinovirus-Induced Disease in Asthmatics

NCT00013715
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2008 · Synced Oct 21, 2026, 2:41 AM EDT
Terminated Phase 3 Interventional Results available

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

NCT04489381
View directory record Official record
Conditions
Enterovirus, Rhinovirus
Interventions
Nitazoxanide, Placebo, Vitamin Super B-Complex
Drug · Dietary Supplement
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
12 Years to 120 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Hot Springs, Arkansas • Fort Lauderdale, Florida • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Not applicable Interventional Results available

Effect of Montelukast on Experimentally-Induced RV16 Infection in Asthma

NCT00359073
View directory record Official record
Conditions
Asthma
Interventions
montelukast, placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

NCT01175226
View directory record Official record
Conditions
Rhinovirus
Interventions
BTA798, Placebo
Drug
Lead sponsor
Biota Scientific Management Pty Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
43
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Results available

PVSRIPO for Recurrent Glioblastoma (GBM)

NCT01491893
View directory record Official record
Conditions
GBM, Glioblastoma, Glioma, Malignant Glioma
Interventions
Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Lerapolturev in Recurrent Malignant Glioma

NCT02986178
View directory record Official record
Conditions
Malignant Glioma
Interventions
lerapolturev, Lomustine
Biological · Drug
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 21, 2026, 2:41 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study

NCT07342582
View directory record Official record
Conditions
Rhinovirus
Interventions
Nasal Swab Healthy Surveillance, Nasal Swab Sick Samples, Nasal Swab Hospitalized Cohort, Sick Follow-up Survey, Older Cohort Control Group, Procedural Comfort or Care
Diagnostic Test · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 17 Years
Enrollment
670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Transfer Factor to Prevent Upper Respiratory Tract Infections in Healthy Adults

NCT01106183
View directory record Official record
Conditions
Upper Respiratory Tract Infections Due to Influenza or Rhinovirus
Interventions
transfer factor, Placebo
Dietary Supplement
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 40 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 21, 2026, 2:41 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

NCT06999603
View directory record Official record
Conditions
Viral Pneumonia
Interventions
SNG001, Placebo
Drug
Lead sponsor
Synairgen Research Ltd.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic

NCT02111772
View directory record Official record
Conditions
Asthma
Interventions
Rhinovirus
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 21, 2026, 2:41 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study of Airway Inflammatory Responses to Experimental Rhinovirus Infection

NCT03508479
View directory record Official record
Conditions
Healthy Volunteers, Rhinovirus
Interventions
RG-HRV16
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

NCT02367313
View directory record Official record
Conditions
Asthma
Interventions
Vapendavir, Placebo
Drug
Lead sponsor
Biota Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Bakersfield, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 21, 2026, 2:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Nasal Samples of Seasonal Allergic Rhinitics

NCT04670627
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Rhinovirus
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Not applicable Interventional Results available

The Respiratory Protection Effectiveness Clinical Trial

NCT01249625
View directory record Official record
Conditions
Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus, Rhinovirus
Interventions
N95 Respirator, Medical/surgical mask
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
2,862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
7
States / cities
Aurora, Colorado • Denver, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 21, 2026, 2:41 AM EDT
Active, not recruiting Not applicable Interventional

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

NCT05864118
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Results available

Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus

NCT02388997
View directory record Official record
Conditions
Asthma
Interventions
omalizumab, Rhinovirus (strain 16)
Drug · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 4 Interventional

Rhinovirus Study With Lactobacillus Rhamnosus GG

NCT01229917
View directory record Official record
Conditions
Respiratory Tract Infections [C08.730]
Interventions
Fruit juice with Lactobacillus rhamnosus GG, version 1, Fruit juice with Lactobacillus rhamnosus GG, version 2, Standard fruit juice
Other
Lead sponsor
Valio Ltd
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses

NCT00762476
View directory record Official record
Conditions
Common Cold
Interventions
3804-250A, 3804-291
Drug
Lead sponsor
The Dial Corporation
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Paramus, New Jersey • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 21, 2026, 2:41 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Efficacy Study of A Lotion to Prevent Common Colds

NCT00993759
View directory record Official record
Conditions
Common Cold, Healthy
Interventions
3804-250A
Drug
Lead sponsor
The Dial Corporation
Industry
Eligibility
18 Years to 40 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2009 · Synced Oct 21, 2026, 2:41 AM EDT
Terminated Phase 4 Interventional Results available

Study Of RV-39 In Patients Who Also Have Asthma

NCT00503009
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol, fluticasone propionate, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers

NCT01769573
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RG-HRV16, Placebo
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans

NCT02796001
View directory record Official record
Conditions
Healthy Volunteers
Interventions
human rhinovirus, no intervention
Biological · Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 21, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Results available

Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children

NCT03043391
View directory record Official record
Conditions
Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma, Atypical Teratoid/Rhabdoid Tumor of Brain, Medulloblastoma, Ependymoma, Pleomorphic Xanthoastrocytoma of Brain, Embryonal Tumor of Brain
Interventions
Polio/Rhinovirus Recombinant (PVSRIPO)
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
12 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 21, 2026, 2:41 AM EDT
Recruiting Phase 2 Interventional

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

NCT07610395
View directory record Official record
Conditions
Rhinovirus Infection
Interventions
VPV 1000 mg, VPV 500 mg, Placebo
Drug · Other
Lead sponsor
Altesa Biosciences, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
37
States / cities
Mobile, Alabama • Tempe, Arizona • Inglewood, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 2:41 AM EDT